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The urokinase-type plasminogen activator (u-PA) is a serine
protease that converts the inert zymogen plasminogen into plasmin
,a protease with broad substrate specificity (Robbins et al, 1967;
Nielsen et al, 1982). Urokinase can bind specifically and with high
affinity (KD .0.5 nM) to a 45–60 kDa, heavily glycosylated, cell
surface receptor (u-PAR) (Vassalli et al, 1985; Stoppelli et al,
1986) comprised of three similar repeats of approximately 90
residues each (Behrendt et al, 1991; Riittinen et al, 1996). The
aminoterminal domain binds the plasminogen activator with the
carboxyterminus domain anchoring the binding protein to the cell
surface via a glycosyl–phosphatidylinositol chain (Behrendt et al,
1991; Riittinen et al, 1996). The 7 exon u-PAR gene is located on
chromosome 19q13 (Vagnarelli et al, 1992; Casey et al, 1994) and
transcription of the gene yields a 1.4-kb mRNA or an alternatively
spliced variant lacking the membrane attachment peptide sequence
(Roldan et al, 1990; Pyke et al, 1993). The amounts of u-PAR are
controlled mainly at the transcriptional level through 398 base
pairs of upstream sequence, but altered message stability and
receptor recycling may represent other means of controlling the
amount of this gene product at the cell surface (Lund et al, 1995;
Lengyel et al, 1996; Shetty et al, 1997; Nykjaer et al, 1997).
The u-PAR is a multi-functional molecule. First, urokinase
bound to the u-PAR activates plasminogen at a much faster rate
than fluid-phase plasminogen activator (Ellis et al, 1991; Higazi
et al, 1995). Second, the binding site clears urokinase–inhibitor
complexes from the extracellular space (Cubellis et al, 1990;
Conese et al, 1994) through a mechanism involving the a2
macroglobulin receptor. Third, it is now evident that the u-PAR
interacts with the extracellular domain of integrins to connect to
the cytoskeleton thereby mediating cell adhesion and migration
(Bohuslav et al, 1995; Wei et al, 1996; Yebra et al, 1996).
In cancer, the u-PAR plays a prominent role in tumour cell inva-
sion and metastasis. Earlier studies have shown that the over-
expression of a human u-PAR cDNA increased the ability of
human osteosarcoma cells to invade into an extracellular matrix-
coated porous filter (Kariko et al, 1993). Conversely, down-regu-
lating u-PAR levels using either antisense expression constructs,
oligonucleotides, or synthetic compounds reduced the ability of
Hep3 squamous cell carcinoma, breast cancer cells and trans-
formed fibroblasts to demonstrate an invasive phenotype in vitro
and in vivo (Kook et al, 1994; Quattrone et al, 1995). Similarly,
Wilhelm et al (1994) demonstrated that soluble u-PAR used as a
scavenger inhibited the in vitro invasion of ovarian cancer cells. In
clinical studies, u-PAR-positive tumour cells in the bone marrow
of gastric cancer patients is an indicator of a metastatically-
relevant population in a pool of minimal residual tumour cells
(Allgayer et al, 1997).
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Summary The urokinase receptor, overexpressed in invasive colon cancer, promotes tumour cell invasion. Since K-Ras is activated in many
colon cancers, we determined if urokinase receptor overexpression is a consequence of this activated oncogene. Accordingly, urokinase
receptor expression was compared in HCT 116 colon cancer cells containing either a mutation-activated K-Ras or disrupted for this oncogene
(by homologous recombination). HCT 116 cells containing the disrupted K-Ras oncogene expressed between 50 and 85% less urokinase
receptor protein compared with the parental HCT 116 cells. Reduced urokinase receptor expression in cells containing the disrupted mutated
K-Ras was not due to a physical impairment of the urokinase receptor gene since phorbol ester treatment was inductive for its expression.
Constitutive urokinase receptor expression in HCT 116 cells required an intact AP-1 motif in the promoter (at –184) and electrophoretic
mobility shifting assays indicated less c-Jun, JunD, c-Fos and Fra-1 bound to this motif in the K-Ras-disrupted cells. Since the urokinase
receptor accelerates proteolysis, laminin degradation was compared in cells containing the mutation-activated and disrupted K-Ras
oncogene. The latter cells displaying fewer urokinase receptors, degraded 80% less laminin. This is the first study to demonstrate a role for
K-Ras as a regulator of the constitutive expression of the urokinase receptor.
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We demonstrated previously that cultured colon cancer cell
lines displaying a large number of u-PAR at the cell surface
(>105 per cell) were more invasive in vitro compared with other
colon cancer cell lines equipped with tenfold fewer binding sites
(Hollas et al, 1991) and that interfering with the binding of uro-
kinase with its receptor to the former group reduced their ability
to degrade laminin (Schlechte et al, 1989; Hollas et al, 1991) and
invade in vitro. These data were consistent with in situ hybridiza-
tion studies localizing u-PAR mRNA to cancer cells in invasive
foci of colon adenocarcinomas (Pyke et al, 1991). As a clinical
corollary, Ganesh and co-workers (Ganesh et al, 1994) showed
that in colon cancer patients, a high u-PAR protein level is a
predictor of a poor 5-year outcome. How then is the u-PAR gene
overexpressed in colon cancer? It is widely documented that
K-Ras is mutated at a high (50%) rate in colon cancer (Ahnen et al,
1998). Considering this observation, we undertook a study to
determine if the high u-PAR protein in a cultured colon cancer cell
line (HCT 116) characterized as having a mutation-activated
K-Ras (Gly13 to Asp13) (Shirasawa et al, 1993) was due to this
activated oncogene. Towards this end, we compared u-PAR
expression in HCT 116 cells containing the mutation-activated
K-Ras with HCT 116 cells in which this gene had been disrupted
by homologous recombination (Shirasawa et al, 1993). We report
that u-PAR expression, as measured at the protein/mRNA levels as
well as by laminin degradation, is decreased in HCT 116 cells in
which the K-Ras oncogene has been ‘knocked out’ and that this is
probably largely a consequence of decreased binding of c-Jun and
c-Fos to a regulatory AP-1-binding motif located in the promoter
region of the u-PAR gene.
MATERIALS AND METHODS
Cell lines
HCT 116 cells and the mutation K-Ras-knocked out cells (HKh-2,
HKe-3 and HK2-8) were grown in McCoys 5A medium supple-
mented with, or without, 10% fetal bovine serum (FBS). The
disruption of the mutation-activated K-Ras in HCT 116 cells
thereby generating HKh-2, Hke-3 and HK2-8 clones was as
described previously (Shirasawa et al, 1993).
Vectors and antibodies
The u-PAR CAT/luciferase reporters consisted of 449 base pairs of
sequence (Wang et al, 1995) stretching from –398 to +51 (relative
to the transcription start site) cloned into pCAT-Basic vector or
pGL3 (Promega, Madison, WI, USA). The mutated AP-1 u-PAR
CAT reporter (AP-1 distal mt u-PAR CAT) has been described
previously (Lengyel et al, 1996). Oligonucleotides were purchased
from Genosys Biotechnologies (The Woodlands, TX, USA).
Supershifting antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The activated c-Ha-ras
expression construct included a 6.6-kb BamHI fragment from the
activated c-Ha-rasEJ oncogene from T24 bladder carcinoma cells
cloned in a pSV2neo plasmid (Nicolson et al, 1990).
Preparation of nuclear extracts and EMSA
Nuclear extracts and electrophoretic mobility shift assay (EMSA)
were carried out as described elsewhere (Lengyel et al, 1996). The
oligonucleotide used corresponding to the sequence of the u-PAR
promoter spanning nucleotides –199/–170. EMSA was per-
formed using nuclear extract (15 mg), 0.6 mg of poly dI/dC and
(2 ´ 104 cpm) of a T4 polynucleotide kinase-labelled (g32P) ATP
oligonucleotide.
Reporter assays
Cells were transfected at 60% confluency using poly-L-ornithine
as described previously (Nead and McCance, 1995). Where indi-
cated, transient transfections were performed in the presence of a
luciferase expression vector (4 mg) and transfection efficiencies
determined by assaying for luciferase activity. CAT activity was
measured as described previously (Lengyel et al, 1996). The
amount of acetylated [14C]chloramphenicol was determined using
a Storm 840 Phosphorimager (Molecular Dynamics, Sunnyvale,
CA, USA) using ImageQuant software. Reporter assays using the
u-PAR promoter fused to a luciferase reporter were as described
by us previously (Allgayer et al, 1999).
Western blotting and ELISA for u-PAR protein
Cells were extracted into a buffer (10 mM Tris pH 7.4, 0.15 M
sodium chloride, 1% Triton X-100, 0.5% NP-40, 20 mg ml–1 apro-
tinin, 1 mM phenylmelthylsulphonyl fluoride, 1 mM EGTA, 1 mM
EDTA) for 10 min at 4°C. Insoluble material was removed by
centrifugation and 750 mg protein of cell extract immunoprecipi-
tated at 4°C for 16 h with 0.25 mg of a polyclonal anti-u-PAR
antibody and protein A agarose beads. The polyclonal antibody
(kindly provided by Dr Andrew Mazar, Angstrom Pharma-
ceuticals, San Diego, CA, USA) was raised in rabbits against
amino acids 1–281 of the human u-PAR and purified on a
Sepharose-immobilized u-PAR column. The immunoprecipitated
material was subjected to standard Western blotting (Burnette,
1981) and the blot probed with 5 mg ml–1 of an anti-u-PAR mono-
clonal antibody (#3931 American Diagnostica, Greenwich, CT,
USA) and an HRP-conjugated goat anti-mouse IgG. Bands
were visualized by enhanced chemiluminescence (Amersham,
Arlington Heights, IL, USA).
u-PAR protein determinations by enzyme-linked immuno-
sorbent assay (ELISA) were performed as described by the manu-
facturer (American Diagnostica, Greenwich, CT, USA).
Northern blotting
The level of steady state urokinase receptor transcript was deter-
mined by Northern analysis (Lengyel et al, 1996). Total cellular
RNA was extracted from 90% confluent cultures using 5.0 M
guanidinium isothiocyanate and purified on a caesium chloride
cushion (5.7 M) by centrifugation at 150 000 g for 20 h. Purified
RNA was electrophoresed in a 1.5% agarose-formaldehyde gel
and transferred to Nytran-modified nylon by capillary action using
10 ´ sodium–saline citrate (SSC). The Northern blot was probed at
42°C with a random primed radiolabelled 0.65-kb cDNA specific
for u-PAR mRNA (Roldan et al, 1990). The blots were washed at
65°C using 0.25 ´ SSC (SSC = 0.15 M sodium chloride, 15 mM
sodium citrate, pH 7.4) in the presence of 0.75% sodium dodecyl
sulphate (SDS). Loading efficiencies were checked by reprobing
the blot with a radioactive cDNA which hybridizes with the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA.1886 H Allgayer et al
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Laminin degradation assays
These were carried out as described previously (Schlechte et al,
1989). Cells were harvested with 3 mM EDTA–PBS (phosphate-
buffered saline), washed twice and seeded (100 000 cells) on
radioactive laminin-coated (2 mg per dish) dishes. The cells were
allowed to attach overnight. Subsequently, cell surface urokinase
receptors were saturated with 5 nM urokinase and the cells washed
extensively to remove the unbound protease. The cells were then
replenished with serum-free medium with, or without, 10 mg ml–1
plasminogen (final concentration). After varying times at 37°C,
aliquots of the culture medium were withdrawn and counted for
radioactivity. Solubilized laminin represents the degraded glyco-
protein (Schlechte et al, 1989).
RESULTS
Effect of a disrupted activated K-Ras on u-PAR
mRNA/protein
HCT 116 colon cancer cells contain an activated K-Ras (Buard et
al, 1996). To determine the role of this activated oncogene in regu-
lating u-PAR expression, the amount of the u-PAR protein/mRNA
was compared in parental HCT 116 cells and their counterparts
(HKh-2, Hke-3 and HK2-8) in which the activated K-Ras was
disrupted by homologous recombination (Shirasawa et al, 1993).
In Western blotting, reactive bands (Mr 45–60 kDa) indistinguish-
able in size to the u-PAR receptor were detected using cellular
extracts from HCT 116 cells (Figure 1A). The diffuse nature of the
bands probably reflects the glycosylation state of the u-PAR
protein (Moller et al, 1993). Cellular extracts generated with the
clone HKh-2, in which the mutation-activated K-Ras had been
‘knocked out’, indicated substantially less of the u-PAR protein
when compared with the parental HCT 116 cells. This difference
was independent of whether the cells were propagated in serum-
free medium (–FBS) or McCoys medium supplemented with 10%
FBS (+ FBS). Extracts from HCT 116 and three independently
derived clones in which the activated K-Ras had been ‘knocked
out’ were also analysed by a commercially available ELISA for
u-PAR protein (Figure 1B). Whereas HCT 116 cells contained
13.0  ± 2.7 ng u-PAR protein–1 mg–1 protein, this value was reduced
by over 50% for clone Hke-3 (5.9 ± 1.5 ng mg–1) and up to 80% for
the HKh-2 clone (2.3 ± 0.4 ng mg–1). It is presently unclear as to
why u-PAR expression was not uniformly reduced in the three
clones. This is unlikely to be due to different levels of expression
of the activated K-Ras since all clones were verified as being
disrupted at this allele as demonstrated by site-specific hybridiza-
tion analysis, Southern blotting and reverse transcription poly-
merase chain reaction (RT-PCR) (Shirasawa et al, 1993).
To corroborate the u-PAR protein data, RNA was extracted and
purified from the cells and analysed for steady-state u-PAR mRNA
by Northern blotting (Figure 1C). The three separate clones
lacking the activated K-Ras contained less u-PAR mRNA
compared with the parental HCT 116 cells. Thus, HKh-2 and
HK2-8 which had the lowest amount of u-PAR protein were char-
acterized as having the least amount of u-PAR mRNA. In contrast,
the Hke-3 clone had both intermediate levels of u-PAR protein and
mRNA.
Stimulation of u-PAR expression by PMA and an
activated c-Ha-ras in HCT 116 cells in which the
activated K-Ras is disrupted
To rule out the possibility that the method of disrupting the
activated K-Ras gene in HCT 116 had also physically disrupted the
u-PAR gene, we determined if an exogenous stimulus previously
shown to be inductive for u-PAR expression (Picone et al, 1989;
Lund et al, 1991) elevated the amount of this protein in HKh-2
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Figure 1 Reduced expression of u-PAR in HCT 116 cells containing a disrupted K-Ras. (A) Cells were grown to 95% confluence in McCoys 5A medium
supplemented with (+ FBS) or without (–FBS) 10% FBS. Subsequently, cells were extracted, equal protein amounts immunoprecipitated with a polyclonal anti-u-
PAR antibody and the material subjected to Western blotting using a monoclonal anti-u-PAR antibody. Immunoreactive bands were visualized by enhanced
chemiluminescence. The positive control consists of cellular extract from the RKO cell line which displays 300 000 binding sites per cell (Boyd et al, 1988).
(B) Cells were grown to 95% confluence in 10% FBS, extracted and assayed for u-PAR protein by an ELISA. (C) Cells were grown as described for (B), RNA
extracted and purified. Purified RNA was analysed by Northern blotting using a 0.65 kb cDNA corresponding to the u-PAR mRNA. The blot was reprobed with a
GAPDH cDNA. The data are typical of duplicate experimentsKnockout of K-Ras oncogene reduces urokinase receptor expression 1887
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cells. Towards this end, HCT 116 and HKh-2 cells were treated
with 100 nM PMA for varying periods of time and analysed for
u-PAR protein by Western blotting (Figure 2A). Expectedly, in the
absence of the phorbol ester, HKh-2 cells contained less u-PAR
protein than the parental HCT 116. In contrast, u-PAR protein was
substantially induced in both HCT 116 and HKh-2 cells by PMA.
Although it appeared that the time frames of induction (maximal
inductions 8 and 23 h for HCT 116 and HKh-2 cells respectively)
were different, the fact that u-PAR expression was inducible by the
phorbol ester indicated that this gene was still subject to control by
external stimuli and hence was not physically impaired.
We were also interested in determining whether the re-expres-
sion of an activated Ras would lead to increased u-PAR expres-
sion. Towards this end, HKh-2 cells were co-transfected with a
u-PAR promoter-regulated luciferase reporter construct and an
activated c-Ha-ras (Nicolson et al, 1990) expression plasmid.
Increasing amounts of the effector plasmid resulted in a dose-
dependent increase in u-PAR promoter activity (Figure 2B). The
highest amount of the c-Ha-ras expression construct led to over a
fivefold induction in u-PAR promoter activity. These results
suggested that the signalling machinery connecting the Ras protein
at the cell surface to nuclear transcription factors regulating u-PAR
promoter activity in HKh-2 cells is intact.
HKh-2 cells degrade laminin at a slower rate than HCT
116 cells
Since one of the functions of the u-PAR is to facilitate plas-
minogen-dependent proteolysis (Ellis et al, 1991), we determined
if laminin degradation by HKh-2 cells was decreased relative to
HCT 116 cells. Cells were harvested non-enzymatically and plated
on culture dishes coated with radioactive laminin. After cell
attachment and saturation of cells surface u-PAR with exogenous
urokinase, plasminogen was added and at various times thereafter,
aliquots of the culture supernatant were counted for radioactivity.
HCT 116 cells rapidly degraded the laminin as measured by the
solubilized product. After 100 min, approximately 420 000 cpm of
radioactivity was released in duplicate experiments (Figure 3).
In contrast, HKh-2 cells solubilized 80% less laminin (about
80 000 cpm) over an identical time frame. These findings are
consistent with the view that disruption of the mutated K-Ras
in HCT 116 colon cancer cells diminishes u-PAR-directed
proteolysis.
Down-regulation of the u-PAR gene in HCT 116 cells
containing a disrupted K-Ras oncogene is partly a
consequence of reduced transactivation of the
promoter through an upstream AP-1 motif
We next determined the mechanism by which u-PAR expression is
down-regulated in the K-Ras ‘knocked out’ HCT 116 cells. Since
we previously demonstrated the requirement of an upstream AP-1
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Figure 2 Phorbol ester induces u-PAR protein synthesis in HCT 116 cells containing a disrupted K-Ras oncogene. (A) HCT 116 and HKh-2 cells at 80%
confluence were treated with PMA (100 nM) for the indicated times after which cellular extracts were generated and analysed for u-PAR protein as described in
the legend to Figure 1A. The positive control consists of cellular extract from the RKO cell line which displays 300 000 binding sites per cell (Boyd et al, 1988).
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Figure 3 HCT 116 cells, in which the activated K-Ras gene is disrupted,
degrades laminin at a slower rate compared with cells containing the
activated oncogene. Cells were harvested non-enzymatically and (105) plated
in serum-free medium (SF) onto radioactive laminin-coated dishes. Cells
were allowed to attach and cell surface u-PAR saturated by a 30-min
incubation with 5 nM exogenous urokinase. After this time, the cells were
washed extensively and supplemented with, or without, plasminogen (Plas).
The cells were cultured for varying times at 37°C after which aliquots of the
culture supernatant were counted for radioactivity. At the end of the
experiment, cells were harvested and enumerated. The data are shown as
average values of duplicate experiments1888 H Allgayer et al
British Journal of Cancer (1999) 80(12), 1184–1891 © 1999 Cancer Research Campaign
motif (184 base pairs upstream of the major transcriptional start
site) for the constitutive expression of the gene in another colon
cancer cell line (RKO) (Lengyel et al, 1996) we speculated that the
high level of u-PAR protein in HCT 116 may similarly be due to
transactivation through this motif. To test this possibility, HCT 116
cells were transiently transfected with a CAT reporter driven by
either the wild-type or the AP-1-mutated u-PAR promoter. The
u-PAR promoter in which the AP-1 motif was mutated, showed
a 50–70% reduction compared with the wild-type promoter
(Figure 4). Thus, the constitutive activity of the u-PAR promoter in
HCT 116 cells is mediated partly through an AP-1 motif at –184.
Since optimal u-PAR expression in HCT 116 required the AP-1
motif at –184, we hypothesized that the amount of transcription
factor(s) bound to this motif would be less using nuclear extract
from HKh-2 cells in which the mutated K-Ras was disrupted.
Towards this end, nuclear extracts were generated from both HCT
116 and HKh-2 cells and mobility shifting experiments performed
using a u-PAR promoter oligonucleotide spanning the AP-1 motif
at –184. Addition of nuclear extract (equal protein) from either
HCT 116 or HKh-2 cells resulted in slower moving bands
(Figure 5). Most of these were specific (parenthesis) since they
were abolished with a 100-fold excess of the non-radioactive
oligonucleotide. More importantly, the intensity of the specific
bands was substantially greater using nuclear extract from HCT
116 cells compared with that generated with HKh-2 cells.
Interestingly, addition of FBS to the HKh-2 cells resulted in some
induction in the amount of transcription factor(s) bound (compare
45- and 15-min treatments with 10% FBS). However, this was in
the absence of increased u-PAR protein synthesis as evident by
Western blotting (Figure 1A). Presumably, this is a consequence of
the requirement of multiple transcription factors for induction of
u-PAR gene expression. Indeed, we recently reported that u-PAR
synthesis is trans-activated by an AP-2a-related factor through a
separate DNA-binding motif (Allgayer et al, 1999).
To identify the trans-acting proteins bound by the oligo-
nucleotide spanning the AP-1 motif (–184) of the u-PAR promoter,
supershifting experiments were performed (Figure 6). Addition of
antibodies to c-Jun, JunD, c-Fos, and Fra-1 further reduced the
mobility of the shifted bands indicating the presence of these
AP-1-binding proteins complexed with the u-PAR promoter
oligonucleotide. Conversely, antibodies to JunB, Fra-2 or FosB
failed to supershift the u-PAR promoter oligonucleotide–protein
complex. Interestingly, the amount of c-Jun, JunD, c-Fos and
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Figure 4 Requirement of an upstream AP-1 motif for u-PAR expression in
HCT 116 cells. HCT 116 cells were transfected with varying amounts of a
CAT reporter regulated by either the wild-type (398 base pairs of flanking
sequence) u-PAR promoter (u-PAR CAT) or the promoter which had been
mutated at the AP-1 motif (AP-1 distal mt u-PAR CAT). Parallel cultures were
transfected with RSV CAT and pSV0 CAT as positive and negative controls
respectively. After 2 days, the cells were extracted and analysed for CAT
reporter activity after normalization for differences in transfection efficiency.
Chloramphenicol conversions were determined using a Storm 840
Phorphorimager. The experiment was carried out twice
Figure 5 HCT 116 cells disrupted for the K-Ras oncogene demonstrate
decreased binding of nuclear factors to the u-PAR promoter AP-1-spanning
sequence. Cells were grown to 95% confluence. The culture medium was
replenished with fresh FBS-containing medium and, after 15 or 45 min,
nuclear extracts generated. Nuclear extracts (15 mg) were incubated with a
radioactive oligonucleotide corresponding to the u-PAR promoter sequence
spanning nucleotides 199/–170 (thus including the AP-1 motif at –184) in the
presence, or absence, of a 100-fold excess of unlabelled oligonucleotide
competitor. Binding complexes were resolved by electrophoresis. The data
are typical of duplicate experiments.
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Figure 6 Decreased binding of c-Fos, c-Jun, JunD and Fra-1 to the u-PAR
AP-1 motif in cells disrupted for the K-Ras oncogene. Nuclear extract (15 mg)
was incubated for 15 min with the oligonucleotide spanning the u-PAR AP-1
motif at –184. Antibodies (1 mg), or as a control IgG (1 mg), were then added
and incubated for an additional 10 min. Bound complexes were resolved in a
5% polyacrylamide gel. The data are representative of duplicate experimentsKnockout of K-Ras oncogene reduces urokinase receptor expression 1889
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Fra-1 bound to the u-PAR promoter oligonucleotide was greater
for HCT 116 nuclear extracts when compared with HKh-2 nuclear
extracts as judged by the greater intensity of the supershifted
bands. Taken together, these data suggest that the lower amount of
u-PAR protein in HKh-2 cells containing a disrupted K-Ras onco-
gene is at least partly a consequence of reduced AP-1-dependent
transactivation of the promoter. These findings are reminiscent of
a recent report demonstrating the accumulation of higher levels
(and increased DNA-binding) of the AP-1-binding proteins, c-Jun
and Fra-1 (Mechta et al, 1997) in cells transformed with the K-Ras
oncogene.
DISCUSSION
The urokinase receptor has previously been shown to be overex-
pressed in invasive colon cancer and this overexpression is associ-
ated with a shorter survival time for patients afflicted with the
cancer (Pyke et al, 1991; Ganesh et al, 1994). However, the initial
stimulus for the elevation in u-PAR protein production has yet to
be determined. Since, K-Ras mutations are common in colon
cancer (Bos, 1989; Ahnen et al, 1998) we hypothesized that this
activated oncogene contributes to the elevated expression of the
urokinase binding site. To answer this question, we compared
u-PAR expression in a colon cancer cell line (HCT 116) previously
described as having an activated K-Ras with HCT 116 cells in
which this oncogene was disrupted by homologous recombination.
Our data clearly show, for the first time, a reduced expression of
the urokinase binding site in the cells in which the activated K-Ras
gene had been ‘knocked out’. Taken together, these data suggest
that u-PAR expression, in at least a sub-population of colon cancer,
is regulated by a mutation-activated K-Ras. However, it should be
emphasized that it is unlikely that elevated u-PAR production in
colon cancer is always a consequence of this mutation. Thus, we
have found instances in which u-PAR expression in cultured colon
cancer is elevated in the absence of a K-Ras mutation (Buard et al,
1996; Lengyel et al, 1997).
Interestingly, in an earlier study, Jankun and co-workers
(Jankun et al, 1991) had shown an increased amount of urokinase
bound to the receptors on fibroblasts transformed with the K-Ras
oncogene. The authors in that publication concluded that the
K-Ras oncogene was increasing the expression of the serine
protease thereby accounting for the increased occupation of the
binding sites. At the same time, it is equally possible that the trans-
formed fibroblasts were manifesting elevated u-PAR expression
thereby capturing more of the protease. However, since u-PAR
expression was not measured directly, it is not clear whether the
K-Ras oncogene increased production of the u-PAR in the
fibroblasts.
Although, the u-PAR expression was reduced by the disruption
of the activated K-Ras gene, by no means was expression elimi-
nated. These findings would indicate that other signalling mecha-
nisms also contribute to u-PAR expression in the HCT 116 colon
cancer cells. For example, it is possible that growth factor
signalling through the normal K-Ras allele (which is intact) main-
tains u-PAR expression. However, this is a less likely possibility
since we found that u-PAR expression was unchanged by growing
the cells in the absence of serum. Alternatively, it may very well be
that signalling events downstream (or in parallel to) (Herrera-Velit
et al, 1997) of K-Ras also contribute to the elevated expression of
the urokinase binding site in HCT 116 colon cancer cells.
Considering the evidence implicating the activated K-Ras in
regulating u-PAR expression, what is the molecular mechanism by
which this is accomplished? For u-PAR expression, the current
and a previous study (Lengyel et al, 1996) have implicated an
upstream AP-1 motif required for the constitutive expression of
the gene in invasive cultured colon cancer. There has been intense
effort to elucidate the downstream molecules that transmit the
signal from Ras to the transcription factors regulating AP-1-
dependent gene expression. For example, it is well recognized that
Ras can signal through the classical c-Raf-1-MEK1, extracellular
signal-regulated kinase (ERK) cascade (Minden, et al 1994) as
well as through the parallel Rac-1, mitogen-activated protein
kinase kinase (MEKK), c-Jun amino-terminal kinase (JNK)
pathway (Minden et al, 1994; Russell et al, 1995) or a separate PI-
3 kinase-dependent pathway (Rodriguez-Viciana et al, 1994;
Winkler et al, 1997). Indeed, it is possible that the K-Ras-regulated
u-PAR expression in HCT 116 cells is ERK-dependent. Thus, we
previously reported that down-regulation of u-PAR expression in
another colon cancer cell line (RKO) could be achieved by the
expression of a dominant negative expression construct to ERK1
or by treatment of cells with an inhibitor of ERK1 activation (PD
098059) (Lengyel et al, 1997). Consistent with this notion is the
finding by us of increased amount of c-Fos bound to the u-PAR
promoter AP-1 motif. It is well known that c-Fos expression is
increased by the ERKs via stimulation of ternary complex forma-
tion on the c-Fos promoter (Gille et al, 1992). On the other hand,
recent studies have shown that the activated K-Ras in HCT 116
cells does not result in a constitutive activation of MEK1 and ERK
(Ohmori et al, 1997). Thus, it may very well be that other
signalling modules in HCT 116 cells are required for regulating u-
PAR expression in response to the K-Ras oncogene. For example,
the involvement of a JNK1-dependent signalling module in the
regulation of u-PAR expression by phorbol ester was demonstrated
by our group (Gum et al, 1998). This MAPK increased AP-1-
dependent gene transcription largely by increasing the transcrip-
tional activity of c-Jun subsequent to its phosphorylation on serine
residues (Hibi et al, 1993; Adler et al, 1994; Minden et al, 1994).
Again, however, previous studies from Ohmori et al (1997) would
indicate otherwise, Thus, these workers found that JNK was not
activated in HCT 116 cells when compared with the clones Hke-3
and HKh-2 in which K-Ras was deleted by homologous recombi-
nation. We can only speculate that the reduced u-PAR expression
in the K-Ras-knocked out cells is due to another signalling
pathway. One potential cascade could be p38, which regulates
c-Fos expression via preventing the activation of the Sap-1A tran-
scription factor (Janknecht et al, 1997). Alternatively, it may be
that the increased c-myc levels (Ohmori et al, 1997) in HCT 116
cells are related, in some way, to the elevated u-PAR levels evident
in this cell line when compared with clones in which the K-Ras
gene was disrupted.
In conclusion we have, for the first time, provided evidence for
a role of an activated K-Ras as a regulator of the overexpression of
the urokinase binding site and consequently plasminogen-depen-
dent extracellular matrix degradation in at least these cultured
colon cancer cell lines.
ACKNOWLEDGEMENTS
We express our appreciation to Dr Yao Wang, The University
of Sydney, Westmead, Australia for supplying the u-PAR
CAT construct. We thank Dr Andrew Mazar (Angstrom1890 H Allgayer et al
British Journal of Cancer (1999) 80(12), 1184–1891 © 1999 Cancer Research Campaign
Pharmaceuticals) for the generous gift of the u-PAR antibody. We
are grateful to Hector Avila and Parham Khanbolooki for excellent
technical assistance. This work was supported by NIH grants ROI
DE10845, ROI CA58311, P50 DE11906 to DB, and a fellowship to
HA (Dr Mildred Scheel Cancer Foundation, Deutsche Krebshilfe,
Bonn, Germany).
REFERENCES
Adler V, Unlap T and Kraft AS (1994) A peptide encoding the c-Jun d domain
inhibits the activity of a c-Jun amino-terminal protein kinase. J Biol Chem 269:
11186–11191
Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, Stemmerman
G, Wells JD, MacDonald JS and Meyskens FL (1998) Ki-ras mutation and p53
overexpression predict the clinical behavior of colorectal cancer: a southwest
oncology group study. Cancer Res 58: 1149–1158
Allgayer H, Heiss MM, Riesenberg R, Grutzner KU, Tarabichi A, Babic R and
Schildberg FW (1997) Urokinase plasminogen activator receptor (uPA-R): one
potential characteristic of metastatic phenotypes in minimal residual tumor
disease. Cancer Res 57: 1394–1399
Allgayer H, Wang H, Wang Y, Heiss MM, Bauer R, Nyormoi O and Boyd D (1999)
Transactivation of the urokinase-type plasminogen activator receptor gene
through a novel promoter motif bound with an activator protein-2a-related
factor. J Biol Chem 274: 4702–4714
Behrendt N, Ploug M, Patthy L, Houen G, Blasi F and Dano K (1991) The ligand-
binding domain of the cell surface receptor for urokinase-type plasminogen
activator. J Biol Chem 266: 7842–7847
Bohuslav J, Horejsi V, Hansmann C, Stockl J, Weidle UH, Majdic O, Bartke I,
Knapp W and Stockinger H (1995) Urokinase plasminogen activator receptor,
B2-integrins, and Src-kinases within a single receptor complex of human
monocytes. J Exp Med 181: 1381–1390
Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682–4689
Boyd D, Florent G, Kim P and Brattain MG (1988) Determination of the levels of
urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 48:
3112–3116
Buard A, Zipfel PA, Frey RS and Mulder KM (1996) Maintenance of growth factor
signalling through Ras in human colon carcinoma cells containing K-ras
mutations. Int J Cancer 67: 539–546
Burnette W (1981) “Western Blotting” Electrophoretic transfer of proteins from
sodium dodecyl sulfate polyacrylamide gels to unmodified nitrocellulose and
radiographic detection with antibody and radioiodinated protein A. Analyt
Biochem 112: 195–203
Casey JR, Petranka JG, Kottra J, Fleenor DE and Rosse WF (1994) The structure of
the urokinase-type plasminogen activator receptor gene. Blood 84: 1151–1156
Conese M, Olson D and Blasi F (1994) Protease nexin-1-urokinase complexes are
internalized and degraded through a mechanism that requires both urokinase
receptor and a2-macroglobulin receptor. J Biol Chem 269: 17886–17892
Cubellis M, Wun T and Blasi F (1990) Receptor-mediated internalization and
degradation of urokinase is caused by its specific inhibitor PAI-1. Eur Mol Biol
Organ 9: 1079–1085
Ellis V, Behrendt N and Dano K (1991) Plasminogen activation by receptor-bound
urokinase. J Biol Chem 266: 12,752–12,758
Ganesh S, Sier CFM, Heerding MM, Griffioen G, Lamers CBH and Verspaget HW
(1994) Urokinase receptor and colorectal cancer survival. Lancet 344: 401–402
Gille H, Sharrocks AD and Shaw PE (1992) Phosphorylation of transcription factor
p62tcf by MAP kinase stimulates ternary complex formation at c-fos promoter.
Nature 358: 414–417
Gum R, Juarez J, Allgayer H, Mazar A, Wang Y and Boyd D (1998) Stimulation of
urokinase-type plasminogen activator receptor expression by PMA requires
JNK1-dependent and -independent signaling modules. Oncogene 17: 213–226
Herrera-Velit P, Knutson KL and Reiner NE (1997) Phosphatidylinositol 3-kinase-
dependent activation of protein kinase C-zeta in bacterial lipopolylsaccharide-
treated human monocytes. J Biol Chem 272: 16445–16452
Hibi M, Lin A, Minden A and Karin M (1993) Identification of an oncoprotein- and
uv-responsive protein kinase that binds and potentiates the c-Jun activation
domain. Genes Dev 7: 2135–2148
Higazi A, Cohen R, Henkin J, Kniss D, Schwartz BS and Cines D (1995)
Enhancement of the enzymatic activity of single-chain urokinase plasminogen
activator by soluble urokinase receptor. J Biol Chem 270: 17375–17380
Hollas W, Blasi F and Boyd D (1991) Role of the urokinase receptor in facilitating
extracellular matrix invasion by cultured colon cancer. Cancer Res 51:
3690–3695
Janknecht OR and Hunter T (1997) Activation of the Sap-1a transcription factor by
the c-Jun N-terminal kinase (JNK) mitogen-activated protein kinase. J Biol
Chem 272: 4219–4224
Jankun J, Maher V and McCormick. J (1991) Malignant transformation of human
fibroblasts correlates with increased activity of receptor-bound plasminogen
activator. Cancer Res 51: 1221–1226
Kariko K, Kuo A, Boyd D, Okada S, Cines D and Barnathan E (1993)
Overexpression of urokinase receptor increases matrix invasion without
altering cell migration in a human osteosarcoma cell line. Cancer Res 53:
3109–3117
Kook YH, Adamski J, Zelent A and Ossowski L (1994) The effect of antisense
inhibition of urokinase receptor in human squamous cell carcinoma on
malignancy. Eur Mol Biol Organ 13: 3983–3991
Lengyel E, Wang H, Gum R, Simon C, Wang Y and Boyd D (1997) Elevated
urokinase-type plasminogen activator receptor expression in a colon cancer
cell line is due to a constitutively activated extracellular signal-regulated
kinase-1-dependent signaling cascade. Oncogene 14: 2563–2573
Lengyel E, Wang H, Stepp E, Juarez J, Doe W, Pfarr CM and Boyd D (1996)
Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-
inducible expression of the urokinase-type plasminogen activator receptor
gene. J Biol Chem 271: 23176–23184
Lund L, Ronne E, Roldan A, Behrendt N, Romer J, Blasi F and Dano K (1991)
Urokinase receptor mRNA level and gene transcription are strongly and rapidly
increased by phorbol myristate acetate in human monocyte-like U937 cells.
J Biol Chem 266: 5177–5181
Lund LR, Ellis V, Ronne E, Pyke C and Dano K (1995) Transcriptional and post-
transcriptional regulation of the receptor for urokinase-type plasminogen
activator by cytokines and tumor promoters in the human lung carcinoma cell
line A549. Biochem J 310: 345–352
Lund LR, Ellis V, Ronne E, Pyke C and Dano K (1995) Transcriptional and post-
transcriptional regulation of the receptor for urokinase-type plasminogen
activator by cytokines and tumor promoters in the human lung carcinoma cell
line A549. Biochem J 310: 345–352
Mechta F, Lallemand D, Pfarr CM and Yaniv M (1997) Transformation by ras
modifies AP1 composition and activity. Oncogene 14: 837–847
Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL
and Karin M (1994a) Differential activation of ERK and JNK mitogen-
activated protein kinases by raf-1 and MEKK. Science 266:
1719–1722
Minden A, Lin A, Smeal T, Derijard B, Cobb M, Davis R and Karin M (1994b)
c-Jun N-terminal phosphorylation correlates with activation of the JNK
subgroup but not the ERK subgroup of mitogen-activated protein kinases. Mol
Cell Biol 14: 6683–6688
Moller L, Pollanen J, Ronne E, Pedersen N and Blasi F (1993) N-linked
glycosylation of the ligand-binding domain of the human urokinase receptor
contributes to the affinity for its ligand. J Biol Chem 268: 11152–11159
Nead MA and McCance DJ (1995) Poly-L-ornithine-mediated transfection of human
keratinocytes. J Invest Dermatol 105: 668–671
Nicolson GL, Gallick GE, Dulski K, Spohn WH, Lembo TM and Tainsky MA
(1990) Lack of correlation between intercellular junctional communication, p21
rasEJ expression, and spontaneous metastatic properties of rat mammary cells
after transfection with c-Ha-ras or neo genes. Oncogene 5: 747–753
Nielsen L, Hansen J, Skriver L, Wilson E, Kaltoft K, Zenthen J and Dano K (1982)
Purification of zymogen to plasminogen activator from human glioblastoma
cells by affinity chromatography with monoclonal antibody. Biochemistry 21:
6410–6415
Nykjaer A, Conese M, Cremona O, Gliemann J and Blasi F (1997) Recycling of the
urokinase receptor upon internalization of the uPA:serpin complexes. Eur Mol
Biol Organ 16: 2610–2620
Ohmori M, Shirasawa S, Furuse M, Okumura K and Sasazuki T (1997) Activated
Ki-ras enhances sensitivity of ceramide-induced apoptosis without c-Jun NH2-
terminal kinase/stress-activated protein kinase or extracellular signal-regulated
kinase activation in human colon cancer cells. Cancer Res 57: 4714–4717
Picone R, Kajtaniak E, Nielsen L, Behrendt N, Mastronicola M, Cubellis MV,
Stoppelli MP, Pedersen S, Dano K and Blasi F (1989) Regulation of urokinase
receptors in monocyte like cells U937 by phorbol ester phorbol myristate
acetate. J Cell Biol 108: 693–702
Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eirksen J, Blasi F and Dano
K (1991) Urokinase-type plasminogen activator is expressed in stromal cells
and its receptor in cancer cells at invasive foci in human colon
adenocarcinomas. Am J Pathol 138: 1059–1067
Pyke C, Eriksen J, Solberg H, Schnack B, Nielsen S, Kristensen P, Lund LR and
Dano K (1993) An alternatively spliced variant of mRNA for the human
receptor for urokinase plasminogen activator. FEBS 326: 69–74Knockout of K-Ras oncogene reduces urokinase receptor expression 1891
British Journal of Cancer (1999) 80(12), 1184–1891 © 1999 Cancer Research Campaign
Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S and Del
Rosso M (1995) Reversion of the invasive phenotype of transformed human
fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor
gene expression. Cancer Res 55: 90–95
Riittinen L, Limongi P, Crippa MP, Conese M, Hernandez-Marrero L, Fazioli F and
Blasi F (1996) Removal of domain D2 or D3 of the human urokinase receptor
does not affect ligand affinity. FEBS Lett 381: 1–6
Robbins KC, Summaria L, Hsieh B and Shah R (1967) The peptide chains of human
plasmin. J Biol Chem 242: 2333–2342
Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ,
Waterfield MD and Downward J (1994) Phosphatidylinositol-3-OH kinase as a
direct target of ras. Nature 370: 527–532
Roldan A, Cubellis M, Masucci M, Behrendt N, Lund L, Dano K, Appella E and
Blasi F (1990) Cloning and expression of the receptor for urokinase
plasminogen activator, a central molecule in cell surface, plasmin dependent
proteolysis. Eur Mol Biol Organ 9: 467–474
Russell M, Lange-Carter CA and Johnson GL (1995) Direct interaction between ras
and the kinase domain of mitogen-activated protein kinase kinase (MEKK1).
J Biol Chem 270: 11757–11760
Schlechte W, Murano G and Boyd DD (1989) Examination of the role of the
urokinase receptor in human colon cancer mediated laminin degradation.
Cancer Res 49: 6064–6069
Shetty S, Kumar A and Idell S (1997) Posttranscriptional regulation of urokinase
receptor mRNA: identification of a novel urokinase receptor mRNA binding
protein in human mesothelioma cells. Mol Cell Biol 17: 1075–1083
Shirasawa S, Furuse M, Yokoyama N and Sasazuki T (1993) Altered growth of
human colon cancer cell lines disrupted at activated. Ki-ras Science 260: 85–88
Stoppelli MP, Tacchetti C, Cubellis M, Corti A, Hearing V, Cassani G, Appella E
and Blasi F (1986) Autocrine saturation of pro-urokinase receptors on human
A431 cells. Cell 45: 675–684
Vagnarelli P, Raimondi E, Mazzieri R, De Carli L and Migantti P (1992) Assignment
of the human urokinase receptor gene (PLAU) to 19q13. Cytogenet Cell Genet
60: 197–199
Vassalli J, Baccino D and Belin D (1985) A cellular binding site for the Mr 55,000
form of the human plasminogen activator, urokinase. J Cell Biol 100: 86–92
Wang Y, Dang J, Johnson LK, Selhamer JJ and Doe WF (1995) Structure of the
human urokinase receptor gene and its similarity to CD59 and the Ly-6 family.
Eur J Biochem 227: 116–122
Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV and Chapman
HA (1996) Regulation of integrin function by the urokinase receptor. Science
273: 1551–1555
Wilhelm O, Weilde U, Rettenberger S, Schmitt M and Graeff H (1994) Recombinant
soluble urokinase receptor as a scavenger for urokinase-type plasminogen
activator (uPA). Inhibition of proliferation and invasion of human ovarian
cancer cells. FEBS Lett 337: 131–134
Winkler DG, Johnson JC, Cooper JA and Vojtek AB (1997) Identification and
characterization of mutations in Ha-Ras that selectively decrease binding to
cRaf-1. J Biol Chem 272: 24402–24409
Yebra M, Parry GCN, Stromblad S, Mackman N, Rosenberg S, Mueller BM and
Cheresh DA (1996) Requirement of receptor-bound urokinase-type
plasminogen activator for integrin avb 5-directed cell migration. J Biol Chem
271: 29393–29399